Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCITRIOL vs DELTALIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
Management of hypocalcemia in patients undergoing chronic renal dialysis,Secondary hyperparathyroidism in patients with chronic kidney disease not yet on dialysis,Hypoparathyroidism (post-surgical, idiopathic, or pseudohypoparathyroidism),Off-label: Vitamin D-dependent rickets type I and II, osteoporosis (as an adjunct)
Adjunctive treatment of hypocalcemia in hypoparathyroidism,Treatment of refractory rickets,Dietary supplementation for vitamin D deficiency
0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
5–8 hours (terminal) in normal renal function; prolonged up to 18–24 hours in chronic kidney disease (CKD) due to reduced clearance.
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
Primarily metabolized in the kidney and intestine via 24-hydroxylase (CYP24A1) to inactive metabolites (e.g., calcitroic acid). No major hepatic cytochrome P450 involvement.
Hepatic hydroxylation to active metabolites (e.g., calcifediol, calcitriol); undergoes enterohepatic recycling.
Renal (fecal after biliary excretion of metabolites): ~10% unchanged in urine; ~70% as metabolites in feces via bile.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
~99% bound to vitamin D-binding protein (DBP) and albumin.
~95% bound primarily to albumin and alpha-1-acid glycoprotein.
0.5–1.0 L/kg (indicates extensive tissue distribution, primarily to kidney, intestine, bone).
Apparent volume of distribution (Vd) is 0.5-1.0 L/kg, indicating moderate tissue distribution.
Oral: ~70% (rapidly absorbed from small intestine). Intravenous: 100%.
Oral: 80-90%; Intramuscular: 90-100% (assumes complete absorption); Intravenous: 100%.
GFR 15-59 m L/min: initial dose 0.25 mcg orally once daily; GFR <15 m L/min: avoid use or use with caution, dose adjustment not established.
No adjustment required for GFR ≥30 m L/min; use with caution and reduce dose by 50% for GFR <30 m L/min; contraindicated in dialysis.
No specific guidelines for Child-Pugh; use with caution in severe hepatic impairment as calcitriol metabolism may be altered.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Neonates and children: initial 0.25 mcg orally once daily; may increase by 0.25 mcg at 2-4 week intervals as needed; maximum 2 mcg/day.
0.01 mg/kg orally once daily, not to exceed 0.5 mg daily; adjust based on response.
Start at low end of dosing range (0.25 mcg once daily) due to possible decreased renal function; monitor serum calcium and phosphorus closely.
Initiate at 0.25 mg orally once daily; titrate slowly due to increased sensitivity and risk of hypotension.
None officially designated by FDA. However, excessive administration may lead to hypercalcemia, hypercalciuria, and hyperphosphatemia, with risk of soft tissue calcification and renal toxicity.
None.
Hypercalcemia risk: avoid excessive dosing; monitor serum calcium, phosphate, and alkaline phosphatase regularly,Hypercalciuria: may cause nephrolithiasis; maintain adequate hydration,Digitalis toxicity: hypercalcemia increases risk; monitor cardiac status,Adynamic bone disease: excessive suppression of PTH in dialysis patients may lead to low bone turnover,Aluminum intoxication: concurrent use of aluminum-containing phosphate binders may increase toxicity
May cause hypercalcemia; monitor serum calcium and phosphate levels regularly. Use with caution in patients with renal impairment, hyperphosphatemia, or sarcoidosis. Avoid use in patients with evidence of vitamin D toxicity.
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcitriol or any component of the formulation,Hyperphosphatemia (unless adequately managed)
Hypercalcemia, hypervitaminosis D, malabsorption syndrome, and known hypersensitivity to vitamin D or any component of the formulation.
High dietary calcium intake may increase risk of hypercalcemia; advise consistent calcium intake per healthcare provider. No specific restrictions with other foods.
No specific food interactions; however, dietary calcium intake should be consistent. High magnesium foods may affect absorption? No. Avoid excessive intake of calcium-rich foods if hypercalcemia risk.
Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcemia) during pregnancy can lead to fetal hypercalcemia, aortic stenosis, retinopathy, and intellectual disability. First trimester: No clear teratogenicity at normal doses. Second and third trimesters: Maternal hypercalcemia from overdosage may cause fetal hypercalcemia and adverse effects. Avoid doses causing maternal serum calcium >11 mg/d L.
FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is highest in the first trimester. Avoid use during pregnancy unless benefit outweighs risk.
Calcitriol is present in breast milk in low concentrations. The M/P ratio is approximately 0.3–0.4. At maternal therapeutic doses, risk to the infant is minimal. Monitor infant serum calcium if maternal high doses are used.
Deltalin is excreted in human milk. The M/P ratio is unknown. Caution is advised; consider the risk of hypercalcemia in the breastfed infant. Monitoring of infant serum calcium is recommended if used.
Pregnancy may increase vitamin D metabolism; however, calcitriol dose adjustments are generally not required for normal pregnancies. In cases of maternal hypoparathyroidism or renal disease, dosing may need adjustment based on serum calcium levels, as increased maternal blood volume and renal clearance may decrease calcitriol levels. Titrate to maintain normocalcemia.
Dose adjustments may be necessary due to increased vitamin D metabolism and clearance during pregnancy. Monitor serum calcium and 25-hydroxyvitamin D to guide dosing. Initial doses may require increase, but avoid supratherapeutic levels.
Monitor serum calcium and phosphate levels regularly; hypercalcemia risk especially with thiazide diuretics or high calcium intake. Calcitriol has a rapid onset (hours) and short half-life, making it ideal for acute management of hypocalcemia. Avoid concurrent use of magnesium-containing antacids due to risk of hypermagnesemia.
Deltalin (ergocalciferol) is a vitamin D2 supplement used for deficiency and prophylaxis. Monitor serum calcium and phosphate levels during therapy. Use caution in patients with hypercalcemia, hypercalciuria, or renal impairment. Deltalin can increase digoxin toxicity risk via hypercalcemia. For rickets, radiographic healing confirms efficacy.
Take exactly as prescribed, usually once daily with or without food.,Do not take additional calcium or vitamin D supplements without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, muscle weakness, confusion, or irregular heartbeat.,Avoid excessive intake of calcium-rich foods (e.g., dairy products) unless advised.,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not double dose if missed.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, or confusion.,Avoid taking with other vitamin D supplements unless directed by healthcare provider.,Inform healthcare provider of all medications, especially digoxin, thiazide diuretics, and antacids.,Store at room temperature away from light and moisture.
"Dexamethasone, a potent glucocorticoid, induces the expression of the enzyme 24-hydroxylase (CYP24A1), which accelerates the catabolism of calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites. This reduces the bioavailability and therapeutic efficacy of calcitriol, potentially leading to inadequate control of hypocalcemia in patients with chronic kidney disease or hypoparathyroidism. Clinically, this interaction may manifest as declining serum calcium levels or worsening bone mineral density despite calcitriol therapy."
"Calcitriol, the active form of vitamin D, may reduce the serum concentration of aripiprazole through a proposed mechanism involving induction of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) efflux transporter. This interaction could lead to decreased systemic exposure of aripiprazole, potentially compromising its antipsychotic efficacy. Clinically, patients may experience worsening of psychotic symptoms or require dose adjustments of aripiprazole when coadministered with calcitriol."
"Calcitriol, the active form of vitamin D, may inhibit the metabolism of delavirdine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), by competing for or downregulating cytochrome P450 (CYP) enzymes, particularly CYP3A4. This can lead to elevated delavirdine plasma concentrations, increasing the risk of dose-related adverse effects such as hepatotoxicity, rash, and central nervous system toxicity. Clinically, patients may experience enhanced delavirdine toxicity without a corresponding increase in antiretroviral efficacy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCITRIOL vs DELTALIN, answered by our medical review team.
CALCITRIOL is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.. DELTALIN is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCITRIOL and DELTALIN depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCITRIOL is: 0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.. The standard adult dose of DELTALIN is: 0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCITRIOL and DELTALIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCITRIOL is classified as Category A/B. Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcem. DELTALIN is classified as Category C. FDA Pregnancy Category D. Vitamin D analogues can cause hypercalcemia, which may lead to fetal supravalvular aortic stenosis, elfin facies, and intellectual disability. Risk is hig. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.